BioCryst Pharmaceuticals
BCRX
91 hedge funds and large institutions have $740M invested in BioCryst Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 32 increasing their positions, 24 reducing their positions, and 26 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 24
33% more capital invested
Capital invested by funds: $555M → $740M (+$184M)
26% more call options, than puts
Call options by funds: $5.83M | Put options by funds: $4.63M
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
11% less funds holding
Funds holding: 102 → 91 (-11)
35% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$16.9M |
| 2 |
QF
QVT Financial
New York
|
+$5.75M |
| 3 |
State Street
Boston,
Massachusetts
|
+$5.06M |
| 4 |
Axa
Paris,
France
|
+$3.6M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$2.83M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$4.66M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$3.31M |
| 3 |
Jennison Associates
New York
|
-$3.14M |
| 4 |
Morgan Stanley
New York
|
-$2.51M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.45M |
BCRX Hedge Fund Activity: Q4 2014 in Review
91 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q4 2014, worth a combined $740M — up 33% from $555M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of BCRX and 17 opened new positions — a net loss of 9 holders — while 24 trimmed existing stakes and 32 added.
The largest buyer was Wellington Management Group, adding an estimated $16.9M. The largest seller was D.E. Shaw & Co, cutting an estimated $4.66M.
- 91 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q4 2014, down from 102 in Q3 2014.
- Funds reported $740M of BioCryst Pharmaceuticals stock for Q4 2014, up 33% quarter-over-quarter.
- 17 funds opened new BioCryst Pharmaceuticals positions in Q4 2014 and 26 closed out, a net change of -9 holders.
- The largest BioCryst Pharmaceuticals buyer in Q4 2014 was Wellington Management Group, an estimated $16.9M added.
- The largest BioCryst Pharmaceuticals seller in Q4 2014 was D.E. Shaw & Co, an estimated $4.66M sold.
Based on aggregated 13F filings for Q4 2014.